Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,705.00
Bid: 1,650.00
Ask: 1,710.00
Change: 0.00 (0.00%)
Spread: 60.00 (3.636%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

Thu, 07th Dec 2023 12:54

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Kelso said that the e-commerce, cosmetics and nutrition company is significantly undervalued by the market, and urged the Manchester-based firm to "do everything they can" to address this.

Kelso, which owns a 0.6% stake in THG, thinks this can be achieved by a separation.

Kelso outlined its conviction in the "substantial value creation opportunity" at the company. It believes THG's sum of parts is well above its current market valuation.

THG, which floated in 2020 with a valuation of some GBP5 billion, has since fallen to a market capitalisation of around GBP1.03 billion.

Throughout the year, Kelso has argued that THG's Nutrition business alone could be worth more than the entire company's market capitalisation.

Kelso pointed to the fact that the company's larger global peers in nutrition and beauty trade on chunkier valuation multiples than THG does.

To resolve this disparity, Kelso has pushed for a demerger. This would "allow each part of the business better access to capital to deliver further growth and build upon their market leading positions".

Kelso cited Whitbread PLC's successful demerger of Costa Coffee in 2018 and GSK PLC's consumer healthcare business Haleon PLC in July 2021 as inspiration to draw on.

Kelso said that the UK stock market would not ascribe a sum-of-parts valuation to THG "until the company publicly confirms its intention to demerge its businesses".

Kelso also warned THG it could be in play for a takeover tilt. Kelso cautioned on the prospect of an opportunistic bid given the THG's low share price, arguing that a "supportive shareholder base" was essential to mitigate this risk.

Kelso Chief Executive Officer John Goold stated: "We believe that the market would respond well to a formal confirmation of a demerger of THG... We hope that THG adopts our beliefs and announces a strategy for the demerger of its three stand-out global businesses without further delay."

THG's founder and Chief Executive Officer Matthew Moulding recently acquired a 3.2% stake in Kelso Group.

THG made its London Stock Exchange debut back in September 2020. Life as a listed company has not been plain-sailing for the company since then.

Shares floated at 500 pence each. The stock rose 0.8% at 78.98p each in London on Thursday afternoon, some 84% off its IPO price.

Kelso traded 3.4% at 3.05p each on Thursday.

By Hugh Cameron, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more
30 Apr 2024 12:22

Sensodyne-maker Haleon to shut UK plant, 435 jobs to go

April 30 (Reuters) - Haleon, the world's largest standalone consumer healthcare firm, will shut its UK production site which makes Sensodyne toothpastes by 2026, leading to 435 job losses, a spokesperson said on Tuesday.

Read more
25 Apr 2024 15:53

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.